Thomas Metz
Impact in
-
- interferon and immune responses
- Immune Cell Function and Interaction
-
- Acute Myeloid Leukemia Research
Papers in
-
- Cancer Genomics and Diagnostics 5
-
- interferon and immune responses 3
Thomas Metz
20 papers receiving 423 citations
Peers
Comparison fields: 5 of 54
- Immunology 106
- Hematology 54
- Oncology 128
- Molecular Biology 284
- Virology 15
Countries citing papers authored by Thomas Metz
This map shows the geographic impact of Thomas Metz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Metz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Metz more than expected).
Fields of papers citing papers by Thomas Metz
This network shows the impact of papers produced by Thomas Metz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Metz. The network helps show where Thomas Metz may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Metz, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2019 | 1 | |
| 2 | 2016 | 0 | |
| 3 | 2015 | 1 | |
| 4 | 2013 | 2 | |
| 5 | 2011 | 1 | |
| 6 | Determination of a 35 gene signature predictive for the effectiveness of Bevacizumab | 2007 | 1 |
| 7 | Gene signature-based prediction of tumor response to cyclophosphamide. | 2007 | 8 |
| 8 | Gene signatures developed from patient tumor explants grown in nude mice to predict tumor response to 11 cytotoxic drugs. | 2007 | 28 |
| 9 | 2006 | 8 | |
| 10 | 2006 | 1 | |
| 11 | A comparative cell-based high throughput screening strategy for the discovery of selective tyrosine kinase inhibitors with anticancer activity. | 1999 | 7 |
| 12 | 1996 | 10 | |
| 13 | 1995 | 103 | |
| 14 | 1994 | 28 | |
| 15 | Oncogenes and erythroid differentiation. | 1994 | 9 |
| 16 | The nuclear oncogenes v-erbA and v-ets cooperate in the induction of avian erythroleukemia. | 1992 | 12 |
| 17 | 1991 | 77 | |
| 18 | 1991 | 33 | |
| 19 | 1991 | 77 | |
| 20 | A point mutation in the DNA binding domain of the v-myb oncogene of E26 virus confers temperature sensitivity for transformation of myelomonocytic cells. | 1988 | 24 |
About Thomas Metz
Thomas Metz is a scholar working on Cancer Research, Immunology, Biotechnology, Oncology and Radiology, Nuclear Medicine and Imaging, having authored 22 papers that have together received 434 indexed citations. Recurring topics across this work include Cancer Genomics and Diagnostics (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Virus-based gene therapy research (3 papers), interferon and immune responses (3 papers), Protein Degradation and Inhibitors (2 papers), Cancer Research and Treatments (2 papers), HER2/EGFR in Cancer Research (2 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Immunology (106 citations), Hematology (54 citations), Oncology (128 citations), Molecular Biology (284 citations) and Virology (15 citations). Thomas Metz has collaborated with scholars based in Germany, Australia and Austria. Frequent co-authors include Thomas Graf, Jerry M. Adams, Alan W. Harris, Achim Leutz, Heinz‐Herbert Fiebig, Hartmut Beug, Julia Schüler, Michael Hofmann, Tyler Jacks and Lynn M. Corcoran. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Cell, The EMBO Journal and Genes & Development.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.